Abstract
Apoptosis is involved in the action of several (and perhaps all) cancer-chemotherapeutic agents. Prodigiosins, a family of natural red pigments characterized by a common pyrrolylpyrromethene skeleton, are produced by various bacteria. Three members of the prodigiosin family, viz. prodigiosin (PG), undecylprodigiosin (UP) and cycloprodigiosin hydrochloride (cPrG HCl), have immunosuppressive properties and apoptotic effects on cancer cells in vitro and in vivo. Their cytotoxic effect is attributed to the presence of the C-6 methoxy substituent. The A-pyrrole ring plays a key role in both the copper nuclease activity and the cytotoxicity of prodigiosins. Here, we have reviewed the pharmacological activity of PG and related compounds, including novel synthetic PG-derivatives with lower toxicity. The mechanism of action for these molecules is a current topic in biomedicine. The molecular targets of prodigiosins are also discussed.
Keywords: prodigiosin, anticancer drug, prodigiosin family, pg, undecylprodigiosin
Current Cancer Drug Targets
Title: The Prodigiosins: A New Family of Anticancer Drugs
Volume: 3 Issue: 1
Author(s): Beatriz Montaner and Ricardo Pérez-Tomás
Affiliation:
Keywords: prodigiosin, anticancer drug, prodigiosin family, pg, undecylprodigiosin
Abstract: Apoptosis is involved in the action of several (and perhaps all) cancer-chemotherapeutic agents. Prodigiosins, a family of natural red pigments characterized by a common pyrrolylpyrromethene skeleton, are produced by various bacteria. Three members of the prodigiosin family, viz. prodigiosin (PG), undecylprodigiosin (UP) and cycloprodigiosin hydrochloride (cPrG HCl), have immunosuppressive properties and apoptotic effects on cancer cells in vitro and in vivo. Their cytotoxic effect is attributed to the presence of the C-6 methoxy substituent. The A-pyrrole ring plays a key role in both the copper nuclease activity and the cytotoxicity of prodigiosins. Here, we have reviewed the pharmacological activity of PG and related compounds, including novel synthetic PG-derivatives with lower toxicity. The mechanism of action for these molecules is a current topic in biomedicine. The molecular targets of prodigiosins are also discussed.
Export Options
About this article
Cite this article as:
Montaner Beatriz and Pérez-Tomás Ricardo, The Prodigiosins: A New Family of Anticancer Drugs, Current Cancer Drug Targets 2003; 3 (1) . https://dx.doi.org/10.2174/1568009033333772
DOI https://dx.doi.org/10.2174/1568009033333772 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Codon Usage Patterns in the Human Papillomavirus Oncogenes
Current Bioinformatics “Micromanaging” Glioblastoma Multiforme: The Potential of MicroRNAs, Circular RNAs, and the Hippo Pathway as Novel Treatment Strategies
Current Neurovascular Research The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Bioinformatics Approach for Data Capturing: The Case of Breast Cancer
Current Cancer Therapy Reviews The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Modulation of Cellular Function by TAT Mediated Transduction of Full Length Proteins
Current Protein & Peptide Science From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma
Current Drug Delivery Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
Current Cancer Drug Targets The Different Roles of The Channel-Kinases TRPM6 and TRPM7
Current Medicinal Chemistry NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry An Update on Molecular Research of Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening